CALML5 and Alzheimer disease: Using samples from AD patients and aged APP/PS1 mice, we next investigated whether the CLSP activity, which is dominantly regulated by the adiponectin level and likely correlates with the intraneuronal SH3BP5 level, was reduced in the CNS of AD.